STACEY SHEPARD
Pharmacy in Wilmington, DE
License number
Pennsylvania RP043444R
Category
Pharmacy
Type
Pharmacist
Address
Address
2
Wilmington, DE 19803
Pennsylvania
Pennsylvania
Personal information
See more information about STACEY SHEPARD at radaris.comName
Address
Phone
2200 Inglewood Rd APT C, Wilmington, DE 19803
2017 Polo Run Dr, Morrisville, PA 19067
2200 Inglewood Rd, Wilmington, DE 19803
1925 Waverly St, Philadelphia, PA 19146
2017 Polo Run Dr, Morrisville, PA 19067
Professional information
Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
US Patent:
2013013, May 30, 2013
Filed:
Jan 30, 2013
Appl. No.:
13/754533
Inventors:
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Assignee:
INCYTE CORPORATION - Wilminton DE
International Classification:
A61K 31/541, C07D 471/04, A61K 31/519, C07D 487/04, A61K 31/5377, A61K 31/513
US Classification:
5142285, 546113, 514300, 544333, 514256, 544280, 5142651, 544117, 5142342, 544 582, 435184
Abstract:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Cyclobutyl Substituted Pyrrolopyridine And Pyrrolopyrimidine Derivatives As Jak Inhibitors
US Patent:
2012014, Jun 14, 2012
Filed:
Nov 18, 2011
Appl. No.:
13/300094
Inventors:
JAMES D. RODGERS - Landenberg PA, US
Stacey Shepard - Wilmington DE, US
Wenyu Zhu - Media PA, US
Lixin Shao - Newark DE, US
Joseph Glenn - Mount Royal NJ, US
Stacey Shepard - Wilmington DE, US
Wenyu Zhu - Media PA, US
Lixin Shao - Newark DE, US
Joseph Glenn - Mount Royal NJ, US
International Classification:
A61K 31/519, C07D 471/04, A61K 31/506, A61K 31/5377, A61P 37/00, A61P 35/00, A61P 29/00, A61P 19/08, A61P 37/06, A61P 17/00, A61P 25/00, A61P 19/02, A61P 3/10, A61P 19/04, A61P 1/00, A61P 21/04, A61P 1/16, A61P 9/10, A61P 5/12, A61P 17/06, A61P 35/02, A61P 19/10, C12N 9/99, C07D 487/04
US Classification:
51421021, 544280, 51425216, 51425211, 5142651, 544295, 51425218, 544117, 5142342, 435184
Abstract:
The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I:wherein X, Y, Z, L, A, R, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Metabolites Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
US Patent:
7834022, Nov 16, 2010
Filed:
Jun 12, 2008
Appl. No.:
12/137883
Inventors:
James D. Rodgers - Landenberg PA, US
Argyrios G. Arvantis - Kennett Square PA, US
Jack Guoen Shi - Wilmington DE, US
Stacey Shepard - Wilmington DE, US
Argyrios G. Arvantis - Kennett Square PA, US
Jack Guoen Shi - Wilmington DE, US
Stacey Shepard - Wilmington DE, US
Assignee:
Incyte Corporation - Wilmington DE
International Classification:
C07D 487/04, A61K 31/519, A61P 37/06, A61P 35/00, A61P 25/28
US Classification:
5142651, 544265
Abstract:
The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
US Patent:
2011022, Sep 15, 2011
Filed:
Mar 9, 2011
Appl. No.:
13/043986
Inventors:
Taisheng Huang - Wilmington DE, US
Anlai Wang - Wilmington DE, US
Ling Quan Kong - Hockessin DE, US
Hai Fen Ye - Newark DE, US
Wenqing Yao - Kennett Square PA, US
James D. Rodgers - Landenberg PA, US
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Lixin Shao - Newark DE, US
Hui-Yin Li - Hockessin DE, US
Qun Li - Newark DE, US
Anlai Wang - Wilmington DE, US
Ling Quan Kong - Hockessin DE, US
Hai Fen Ye - Newark DE, US
Wenqing Yao - Kennett Square PA, US
James D. Rodgers - Landenberg PA, US
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Lixin Shao - Newark DE, US
Hui-Yin Li - Hockessin DE, US
Qun Li - Newark DE, US
International Classification:
A61K 31/519, C07D 487/04, C07D 471/04, C12N 9/99, A61P 35/00, A61P 19/02, A61P 25/00, A61P 17/00, A61P 29/00, A61P 19/08, A61P 17/06, A61P 35/02
US Classification:
51421021, 544280, 546113, 544333, 544405, 435184
Abstract:
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Pyrazolyl Substituted Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
US Patent:
8415362, Apr 9, 2013
Filed:
Jun 12, 2008
Appl. No.:
12/138082
Inventors:
James D. Rodgers - Landenberg PA, US
Stacey Shepard - Wilmington DE, US
Thomas P. Maduskuie - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Stacey Shepard - Wilmington DE, US
Thomas P. Maduskuie - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Assignee:
Incyte Corporation - Wilmington DE
International Classification:
C07D 487/04, A61K 31/519, A61K 31/437, C07D 471/04, A61P 35/00, A61P 29/00
US Classification:
5142651, 544280, 514300, 546113
Abstract:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I:.
Metabolites Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
US Patent:
2011008, Apr 7, 2011
Filed:
Oct 7, 2010
Appl. No.:
12/900180
Inventors:
James D. RODGERS - Landenberg PA, US
Argyrios G. ARVANITIS - Kennett Square PA, US
Jack Guoen SHI - Wilmington DE, US
Stacey SHEPARD - Wilmington DE, US
Argyrios G. ARVANITIS - Kennett Square PA, US
Jack Guoen SHI - Wilmington DE, US
Stacey SHEPARD - Wilmington DE, US
Assignee:
INCYTE CORPORATION - Wilmington DE
International Classification:
A61K 31/519, C07D 487/04, A61P 35/00, A61P 29/00, A61P 9/10, A61P 37/06, A61P 17/00, A61P 17/06, A61P 31/12, C12N 9/99
US Classification:
5142651, 544280, 435184
Abstract:
The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
US Patent:
2014001, Jan 16, 2014
Filed:
Sep 20, 2013
Appl. No.:
14/033039
Inventors:
James D. Rodgers - Landenberg PA, US
Stacey Shepard - Wilmington DE, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Stacey Shepard - Wilmington DE, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Assignee:
INCYTE CORPORATION - Wilmington DE
International Classification:
C07D 487/04, A61K 31/519, A61K 45/06
US Classification:
5142651
Abstract:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
US Patent:
2014000, Jan 2, 2014
Filed:
Sep 6, 2013
Appl. No.:
14/020505
Inventors:
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Haisheng Wang - Hockessin DE, US
Nikoo Falahatpisheh - Wilmington DE, US
Maria Rafalski - Greenville DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Louis Storace - Middletown DE, US
Ravi Kumar Jalluri - Avondale PA, US
Jordan S. Fridman - Newark DE, US
Krishna Vaddi - Kennett Square PA, US
Assignee:
Incyte Corporation - Wilmington DE
International Classification:
C07D 487/04
US Classification:
5142651
Abstract:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Heterocyclic Derivatives Of Pyrazol-4-Yl-Pyrrolo[2,3-D]Pyrimidines As Janus Kinase Inhibitors
US Patent:
2011005, Mar 10, 2011
Filed:
Aug 31, 2010
Appl. No.:
12/872925
Inventors:
James D. Rodgers - Landenberg PA, US
Yun-Long Li - Chadds Ford PA, US
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
Yun-Long Li - Chadds Ford PA, US
Stacey Shepard - Wilmington DE, US
Haisheng Wang - Hockessin DE, US
International Classification:
A61K 31/551, C07D 487/04, A61K 31/519, A61P 19/00, A61P 37/06, A61P 29/00, A61P 35/00, A61P 17/00, C12N 9/12
US Classification:
514218, 544280, 51425216, 5142651, 540575, 435194
Abstract:
The present invention provides heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Hydroxyl, Keto, And Glucuronide Derivatives Of 3-(4-(7H-Pyrrolo[2,3-D] Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
US Patent:
8486902, Jul 16, 2013
Filed:
Oct 8, 2010
Appl. No.:
12/901001
Inventors:
James D. Rodgers - Landenberg PA, US
Adam Shilling - Wilmington DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Stacey Shepard - Wilmington DE, US
Laurine G. Galya - Wilmington DE, US
Mei Li - Wilmington DE, US
Frank M. Nedza - Wilmington DE, US
Adam Shilling - Wilmington DE, US
Argyrios G. Arvanitis - Kennett Square PA, US
Stacey Shepard - Wilmington DE, US
Laurine G. Galya - Wilmington DE, US
Mei Li - Wilmington DE, US
Frank M. Nedza - Wilmington DE, US
Assignee:
Incyte Corporation - Wilmington DE
International Classification:
C07H 17/02, C07D 487/04, A61K 31/70, A61K 31/519, A61P 37/06, A61P 35/00, A61P 25/28, A01N 43/04
US Classification:
514 35, 514 27, 5142651, 536 174, 536 181, 544265, 544180
Abstract:
The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.